Objective
to assess efficacy and safety of rivaroxaban in addition to aspirin in patients with PAD and recent revascularisation
Study
multicentre, double-blind, randomised trial
Population
patients with peripheral artery disease who had undergone revascularisation
Endpoints
primary efficacy outcome was a composite of acute limb ischemia, major amputation for vascular causes, MI, ischemic stroke, or death from cardiovascular causes. The principle safety outcome was major bleeding.
Conclusion
Rivaroxaban lowered the risk of major vascular complications compared with placebo without a significant increase in TIMI major bleeding
Bonaca et al. N Eng J Med. 2020;382:1994-2004
